Literature DB >> 21358731

Eribulin mesylate.

Timothy K Huyck, William Gradishar, Fil Manuguid, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21358731     DOI： 10.1038/nrd3389

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

1.  Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

Authors:  Donnette A Dabydeen; James C Burnett; Ruoli Bai; Pascal Verdier-Pinard; Sarah J H Hickford; George R Pettit; John W Blunt; Murray H G Munro; Rick Gussio; Ernest Hamel
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

2.  Structurally simplified macrolactone analogues of halichondrin B.

Authors:  Boris M Seletsky; Yuan Wang; Lynn D Hawkins; Monica H Palme; Gregory J Habgood; Lucian V DiPietro; Murray J Towle; Kathleen A Salvato; Bruce F Wels; Kimberley K Aalfs; Yoshito Kishi; Bruce A Littlefield; Melvin J Yu
Journal:  Bioorg Med Chem Lett       Date:  2004-11-15       Impact factor: 2.823

Review 3.  The halichondrins and E7389.

Authors:  Katrina L Jackson; James A Henderson; Andrew J Phillips
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

4.  Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Authors:  Chris Twelves; Javier Cortes; Linda T Vahdat; Jantien Wanders; Corina Akerele; Peter A Kaufman
Journal:  Clin Breast Cancer       Date:  2010-04       Impact factor: 3.225

Review 5.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

6.  Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.

Authors:  Armelle Dufresne; Xavier Pivot; Christophe Tournigand; Thomas Facchini; Thierry Altweegg; Loic Chaigneau; Aimery De Gramont
Journal:  Breast Cancer Res Treat       Date:  2007-03-23       Impact factor: 4.872

7.  The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.

Authors:  Mary Ann Jordan; Kathryn Kamath; Tapas Manna; Tatiana Okouneva; Herbert P Miller; Celia Davis; Bruce A Littlefield; Leslie Wilson
Journal:  Mol Cancer Ther       Date:  2005-07       Impact factor: 6.261

Review 8.  Third consensus on medical treatment of metastatic breast cancer.

Authors:  S Beslija; J Bonneterre; H J Burstein; V Cocquyt; M Gnant; V Heinemann; J Jassem; W J Köstler; M Krainer; S Menard; T Petit; L Petruzelka; K Possinger; P Schmid; E Stadtmauer; M Stockler; S Van Belle; C Vogel; N Wilcken; C Wiltschke; C C Zielinski; H Zwierzina
Journal:  Ann Oncol       Date:  2009-07-16       Impact factor: 32.976

9.  Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.

Authors:  Galina Kuznetsov; Murray J Towle; Hongsheng Cheng; Takanori Kawamura; Karen TenDyke; Diana Liu; Yoshito Kishi; Melvin J Yu; Bruce A Littlefield
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

Review 10.  Treatment options for breast cancer resistant to anthracycline and taxane.

Authors:  Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616
View more
  21 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

Review 2.  Natural products as sources of new drugs over the 30 years from 1981 to 2010.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2012-02-08       Impact factor: 4.050

3.  Marine natural products: a new wave of drugs?

Authors:  Rana Montaser; Hendrik Luesch
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 4.  The relevance of higher plants in lead compound discovery programs.

Authors:  A Douglas Kinghorn; Li Pan; Joshua N Fletcher; Heebyung Chai
Journal:  J Nat Prod       Date:  2011-06-08       Impact factor: 4.050

5.  Copper-Catalyzed Enantioselective Hydroalkoxylation of Alkenols for the Synthesis of Cyclic Ethers.

Authors:  Dake Chen; Ilyas A Berhane; Sherry R Chemler
Journal:  Org Lett       Date:  2020-06-04       Impact factor: 6.005

Review 6.  Genomic insights into the marine sponge microbiome.

Authors:  Ute Hentschel; Jörn Piel; Sandie M Degnan; Michael W Taylor
Journal:  Nat Rev Microbiol       Date:  2012-07-30       Impact factor: 60.633

Review 7.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

8.  Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.

Authors:  Takayoshi Kiba; Nao Morii; Hirotoshi Takahashi; Shinji Ozaki; Misao Atsumi; Fumi Masumoto; Yoshimi Shitakubo; Hiroyasu Yamashiro
Journal:  Mol Clin Oncol       Date:  2015-11-05

9.  Antiproliferative homoscalarane sesterterpenes from two Madagascan sponges.

Authors:  Liva Harinantenaina; Peggy J Brodie; Jean Maharavo; Gisele Bakary; Karen TenDyke; Yongchun Shen; David G I Kingston
Journal:  Bioorg Med Chem       Date:  2013-04-06       Impact factor: 3.641

10.  The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.

Authors:  Lisa C Hüsemann; Alina Reese; Claudia Radine; Roland P Piekorz; Wilfried Budach; Dennis Sohn; Reiner U Jänicke
Journal:  Cell Cycle       Date:  2020-01-20       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.